| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
sNDA Submission example | NDA | — | Subscribe to access the data. | RNA-Based Therapies | Cardiovascular System | ||
sNDA Submission example | NDA | — | Subscribe to access the data. | RNA-Based Therapies | Cardiovascular System | ||
sNDA Submission example | NDA | — | Subscribe to access the data. | RNA-Based Therapies | Cardiovascular System |
Recent Updates
Recently added Catalysts
Arrowhead Pharmaceuticals, Inc.
$86.73
-0.38 (-0.44%)
B 68Pipeline Score Fair Value Biotech · Commercial
Market Cap
12.22 B
EPS
-2.10
P/E Ratio
-
Value Trade
75.35 M
-2.22 %
Week
1.4 %
1 Month
10.23 %
3 Month
37.36 %
6 Month
-0.85 %
5 Year
-97.44 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
1.10 M
52 Week Range
20.45 - 95.49
% held by Insiders
5.89 %
% held by Institutions
83.07 %
Enterprise Value
11.30 B
Total Shares
140.92 M
Short %
7.26 %
Float Shares
135.56 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Arrowhead Pharmaceuticals, Inc.
375Total events
9Upcoming
88Tier-1 (high impact)
2010 – 2028Coverage
Upcoming catalysts 2
TBD
T2Oral Presentation
Subscribe to view catalyst details
TBD
T2Timing Guidance
Subscribe to view catalyst details
Event history 2
TBD
▲Product LaunchREDEMPLOApprovedPost-Market
Subscribe to view catalyst details
TBD
●Quarterly UpdateCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2025-11-18 | plozasiran (previously ARO-APOC3) | PDUFA Date | PDUFA | Approved | – | – | – |
2025-11-18 | plozasiran (previously ARO-APOC3) | PDUFA Date | PDUFA | Approved | – | – | – |
2025-11-18 | plozasiran (previously ARO-APOC3) | PDUFA Date | PDUFA | Approved | – | – | – |
Drug Pipeline Intelligence
B68
Pipeline Score $5.6B
Pipeline ValueFair Value
Valuation Signal26
Drugs Scored1.5x
rNPV / MCap Top 95%
Mid Cap (rank 48 of 933)
Percentile RankArrowhead Pharmaceuticals, Inc. holds a solid B-grade pipeline (68/100), with $6.6B risk-adjusted pipeline value, led by Plozasiran in Hypertriglyceridemia (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Plozasiran Small molecule | Hypertriglyceridemia | Phase 3 | NCT06347133 | 86% | $2.3B | ACTIVE NOT_RECRUITING | 2,325 | VERY_FAST | B (76) | Sep 1, 2026 | MODERATE_RISK | LOW Jun 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
plozasiran BreakthroughPriority | severe hypertriglyceridemia | Phase 3 | 2026-07-22 | 79%; 81%; 100%; 27%; 78% | Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia Read More | |
plozasiran BreakthroughPriority | severe hypertriglyceridemia | Phase 3 | 2026-07-22 | 79%; 81%; 100%; 27%; 78% | Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia Read More | |
plozasiran BreakthroughPriority | severe hypertriglyceridemia | Phase 3 | 2026-07-22 | 79%; 81%; 100%; 27%; 78% | Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ARWR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ARWR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-12-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-12-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-12-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ARWR▼ -0.4%today
Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress
Arrowhead Pharmaceuticals announced it will present new clinical data at the European Society of Cardiology Congress in Munich. The presentation will focus on the SHASTA-3 and SHASTA-4 pivotal trial results for Plozasiran in patients with severe hypertriglyceridemia. This event is scheduled for August 30, 2026.
Read more →ARWRPeople Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides
Arrowhead Pharmaceuticals has announced that REDEMPLO® (plozasiran) is now available in Germany for patients with Familial Chylomicronaemia Syndrome (FCS). This new treatment option, authorized by the European Commission in June 2026, aims to significantly reduce high triglyceride levels in affected individuals. Germany is among the first countries in the EU to offer this therapy.
Read more →ARWRArrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results
Arrowhead Pharmaceuticals, Inc. reported its fiscal 2026 third quarter results, highlighting significant financial growth and transformational events that bolster future prospects. The company will discuss these results in a conference call scheduled for August 4, 2026. CEO Christopher Anzalone emphasized the positive developments during this period.
Read more →ARWRArrowhead Pharmaceuticals Acquires FDA Priority Review Voucher
Arrowhead Pharmaceuticals has acquired a Rare Pediatric Disease Priority Review Voucher from an undisclosed third party. This voucher will be used for the Supplemental New Drug Application for plozasiran, which aims to expand its approved indication for pediatric patients. The submission is expected before the end of 2026.
Read more →ARWRArrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Arrowhead Pharmaceuticals announced inducement grants for 95 new employees, approved by the Board of Directors under NASDAQ Rule 5635(c)(4). The grants, totaling up to 112,794 restricted stock units, are designed to incentivize new hires and are outside the company's existing equity incentive plans. This move highlights the company's commitment to expanding its workforce.
Read more →ARWRArrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia
Arrowhead Pharmaceuticals has successfully completed enrollment in its global Phase 3 YOSEMITE study for zodasiran, aimed at treating homozygous familial hypercholesterolemia (HoFH). This investigational RNA interference therapeutic targets a rare genetic disorder that causes high LDL cholesterol levels and early cardiovascular disease. The completion of enrollment marks a significant milestone in the development of this treatment.
Read more →ARWR▲ +19%on this newsshared move
Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia
Arrowhead Pharmaceuticals reported positive topline results from its Phase 3 SHASTA-3 and SHASTA-4 studies of plozasiran, demonstrating significant triglyceride reduction in patients with severe hypertriglyceridemia. This condition poses a high risk of acute pancreatitis, making effective treatment crucial. The studies successfully met their primary endpoint, indicating the drug's potential efficacy.
Read more →ARWRArrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results
Arrowhead Pharmaceuticals has announced a webcast and conference call to discuss its fiscal 2026 third quarter results, scheduled for August 4, 2026. The event will take place at 4:30 p.m. ET and will be accessible via the company's website. A replay will be available shortly after the live event.
Read more →ARWRArrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
Arrowhead Pharmaceuticals has announced that it has received marketing authorization in the European Union for its drug REDEMPLO® (plozasiran). This medication is specifically designed to reduce triglyceride levels in adults suffering from Familial Chylomicronemia Syndrome (FCS). The approval marks a significant milestone for the company in addressing this rare condition.
Read more →ARWRArrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars
Arrowhead Pharmaceuticals is set to host a webinar focusing on its cardiometabolic pipeline. This event is part of the 2026 Summer Series of R&D webinars. Details regarding the specific topics or speakers were not provided in the announcement.
Read more →ARWR▼ -5.8%on this news
Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events
Arrowhead Pharmaceuticals has announced its participation in events scheduled for June 2026. However, the article lacks specific details about the events or the company's agenda. This announcement may indicate the company's ongoing engagement with the industry, but further information is needed to assess its significance.
Read more →ARWRArrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026
Arrowhead Pharmaceuticals has presented new clinical data on its RNAi-based candidate ARO-INHBE targeting obesity and MASH at the EASL 2026 conference. The details of the data and its implications for treatment were not disclosed in the provided text.
Read more →ARWRArrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress
Arrowhead Pharmaceuticals presented new positive clinical data related to cardiometabolic health at the 94th European Atherosclerosis Society Congress. This data highlights the company's ongoing commitment to addressing cardiovascular diseases. The presentation at such a significant event underscores the potential impact of their findings on future treatment strategies.
Read more →ARWRPRESS RELEASE
Arrowhead Pharmaceuticals has reported promising financial results for its fiscal 2026 second quarter, highlighting significant growth in REDEMPLO prescriptions and successful regulatory approvals in various markets. The company anticipates a strong future with growth driven by its robust pipeline of RNAi therapeutics. Key metrics indicating the effectiveness of REDEMPLO in treating patients with familial chylomicronemia syndrome have emerged. Arrowhead also strengthened its financial position through substantial public offerings aimed at enhancing its capital resources.
Read more →ARWRArrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results
Arrowhead Pharmaceuticals has reported its fiscal 2026 second quarter results. The article provides insights into the company's financial performance and operational updates for the period. However, specific details regarding revenue, expenses, or future outlook are not included in the provided text.
Read more →ARWRArrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals
Arrowhead Pharmaceuticals has licensed its clinical MASH program targeting PNPLA3 to Madrigal Pharmaceuticals. This collaboration aims to advance the development of therapies related to this target. Further details on the financial terms or specific goals of the partnership were not disclosed.
Read more →ARWRArrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events
Arrowhead Pharmaceuticals has announced its participation in events scheduled for May 2026. The details regarding the nature of these events and their significance have not been disclosed. The announcement indicates ongoing engagement in the biopharma sector, but further information is awaited.
Read more →ARWRArrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)
Arrowhead Pharmaceuticals has received approval from the Australian Therapeutic Goods Administration for REDEMPLO® (plozasiran), a new treatment for adults with familial chylomicronemia syndrome (FCS). This approval allows the drug to be used as an adjunct to diet to help reduce triglyceride levels in patients who have not responded adequately to standard therapies. The move is expected to improve access to treatment for patients suffering from this rare condition.
Read more →ARWRArrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe
Arrowhead Pharmaceuticals has received a positive opinion from the EMA CHMP recommending the approval of REDEMPLO® (plozasiran) for reducing triglyceride levels in adults with familial chylomicronemia syndrome (FCS). This siRNA medicine is intended as an adjunct to diet. FCS is a condition that is often underdiagnosed, impacting a significant number of individuals.
Read more →ARWRArrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter Results
Arrowhead Pharmaceuticals will host a webcast on May 7, 2026, to discuss its fiscal 2026 second quarter results. The event will take place at 4:30 p.m. ET, with a live audio webcast accessible on their website. Analysts can participate by registering for the conference call to receive dial-in details.
Read more →ARWRArrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and Expo
Arrowhead Pharmaceuticals presented long-term efficacy and safety data for plozasiran at the ACC's 75th Annual Scientific Session. The study showed significant triglyceride reductions, with 83% in severe hypertriglyceridemia patients and no acute pancreatitis events. The findings support plozasiran's potential as a treatment for various hypertriglyceridemia patients.
Read more →ARWRArrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events
Arrowhead Pharmaceuticals has announced its participation in several healthcare conferences scheduled for March 2026. These events include the TD Cowen 46th Annual Health Care Conference and the Barclays 28th Annual Global Healthcare Conference, among others. The company aims to present its advancements in RNA interference therapies, which target intractable diseases.
Read more →ARWRArrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results
Arrowhead Pharmaceuticals reported strong financial results for the first quarter of fiscal 2026, highlighting significant achievements including regulatory approvals for REDEMPLO in three countries and the launch of its first commercial product in the U.S. The company also noted progress in its cardiometabolic portfolio and early successes in obesity programs. CEO Christopher Anzalone expressed confidence in the company's position for future growth.
Read more →ARWRArrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
Arrowhead Pharmaceuticals has initiated a Phase 1/2a clinical trial for ARO-DIMER-PA, a dual-functional RNAi therapeutic aimed at treating mixed hyperlipidemia. This innovative treatment targets both PCSK9 and APOC3 genes, potentially reducing the risk of atherosclerotic cardiovascular disease. The study will evaluate the safety and efficacy of ARO-DIMER-PA in adult subjects.
Read more →ARWRArrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results
Arrowhead Pharmaceuticals will host a webcast on February 5, 2026, to discuss its financial results for the first quarter of fiscal 2026. The event will be accessible to investors via a live audio webcast, with a replay available shortly after. Analysts can participate by registering in advance to receive dial-in details.
Read more →ARWR4 Next-Gen Candidates That Could Form the Future of Alzheimer’s Treatment
The article discusses the emergence of next-generation Alzheimer's treatments following a history of high failure rates in drug development. Companies like Biogen and Arrowhead are advancing innovative therapies targeting tau proteins through various modalities, including antisense oligonucleotides and RNA interference. The potential for combination therapies is highlighted as a key strategy for effective treatment, with significant clinical trial results expected in the coming years.
Read more →ARWR▲ +10.8%on this newsshared move
Document
Arrowhead Pharmaceuticals has announced interim results from Phase 1/2a clinical trials for its RNAi-based obesity treatments, ARO-INHBE and ARO-ALK7. The data indicates that ARO-INHBE, when combined with tirzepatide, results in nearly double the weight loss compared to tirzepatide alone, and shows significant reductions in visceral, total, and liver fat. ARO-ALK7 is noted for successfully silencing a gene in humans, marking a first for RNAi therapeutics targeting fat storage. The company plans to provide further data in 2026 and is actively seeking to address unmet clinical needs in obesity treatments.
Read more →ARWR▼ -5.8%on this newsshared move
Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
Arrowhead Pharmaceuticals has received Health Canada approval for REDEMPLO (plozasiran), the first siRNA treatment for adults with familial chylomicronemia syndrome (FCS). This approval follows positive results from the Phase 3 PALISADE study, demonstrating significant reductions in triglycerides and acute pancreatitis incidents. REDEMPLO can be self-administered at home every three months, offering a new option for patients inadequately treated by standard therapies.
Read more →ARWRArrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events
Arrowhead Pharmaceuticals has announced its participation in two key events in January 2026. The first is an Obesity KOL Webinar focusing on ARO-INHBE and ARO-ALK7 interim clinical data, scheduled for January 6. The second event is the J.P. Morgan 2026 Healthcare Conference from January 12-15, where the company will present corporate updates.
Read more →ARWRArrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia
Arrowhead Pharmaceuticals has received FDA Breakthrough Therapy designation for plozasiran, aimed at reducing triglyceride levels in adults with severe hypertriglyceridemia. This designation will expedite the drug's development and review process, addressing a significant unmet medical need. The company plans to complete Phase 3 studies by mid-2026 and submit a supplemental New Drug Application by the end of 2026.
Read more →ARWRArrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences
Arrowhead Pharmaceuticals has announced its participation in several upcoming conferences in December 2025. Notable events include the Piper Sandler 37th Annual Healthcare Conference and the 8th Annual Evercore Healthcare Conference, where the company will present findings related to Plozasiran. Additionally, the World Congress of Insulin Resistance, Diabetes and Cardiovascular Disease will feature multiple presentations on relevant studies.
Read more →ARWR▼ -7.4%on this newsshared move
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE J&S EPPERS 2005 REVOCABLE ) TRUST, JOHN EPPERS, THE ) GABRIELLE EPPERS SUT-TR, ) and, PHILLIP JACKSON, ) derivatively on behalf of ) ARROWHEAD ) PHARMACEUTICALS, INC., )
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE J&S EPPERS 2005 REVOCABLE ) TRUST, JOHN EPPERS, THE ) GABRIELLE EPPERS SUT-TR, ) and, PHILLIP JACKSON, ) derivatively on behalf of ) ARROWHEAD ) PHARMACEUTICALS, INC., ) ) Plaintiffs, ) ) v. ) C.
Read more →ARWRTakeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease Potential first-in-class therapy designed to treat the underlying cause of liver d
Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease Osaka, JAPAN, and Pasadena, CALIF., October 08, 2020 - Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") and Arrowhead Pharmaceuticals
Read more →ARWRARROWHEAD PHARMACEUTICALS Arrowhead/Amgen Collaboration Prepared Remarks
ARROWHEAD PHARMACEUTICALS Collaboration Prepared Remarks 6:00 AM Pacific time Ladies and gentlemen welcome to the Arrowhead Pharmaceuticals conference call. Throughout today s recorded presentation all participants will be in a listen-only mode. After the presentation there w
Read more →ARWRAMGEN AND ARROWHEAD PHARMACEUTICALS ANNOUNCE TWO CARDIOVASCULAR COLLABORATIONS Amgen to Receive Worldwide Exclusive License to Arrowhead s RNAi ARC-LPA Program Amgen Receives Exclusive License Option to RNAi
AMGEN AND ARROWHEAD PHARMACEUTICALS ANNOUNCE TWO CARDIOVASCULAR COLLABORATIONS Amgen to Receive Worldwide Exclusive License to Arrowhead s RNAi ARC-LPA Program Amgen Receives Exclusive License Option to RNAi Therapy for Undisclosed Cardiovascular Target Arrowhead to Receive $
Read more →ARWRArrowhead Reports Fiscal 2014 Third Quarter Financial Results and Provides Update on ARC-520 - Conference Call Today at 4:30 p.m. EDT PASADENA, Calif.--(BUSINESS WIRE)
Reports Fiscal 2014 Third Quarter Financial Results and Provides Update Conference Call Today at 4:30 p.m. EDT PASADENA, Calif.--(BUSINESS WIRE)--August 12, 2014--Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics,
Read more →ARWRArrowhead Reports Fiscal 2014 Second Quarter Financial Results - Conference Call Today at 4:30 p.m. EDT PASADENA, Calif.--(BUSINESS WIRE)
Reports Fiscal 2014 Second Quarter Financial Results Conference Call Today at 4:30 p.m. EDT PASADENA, Calif.--(BUSINESS WIRE)--May 6, 2014--Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced financ
Read more →ARWRINVESTOR SUBSCRIPTION AGREEMENT This Investor Subscription Agreement (this Agreement ) is entered into on January , 2013 by and between Arrowhead Research Corporation, a Delaware corporation (the Company ), and the Purch
INVESTOR SUBSCRIPTION AGREEMENT This Investor Subscription Agreement (this Agreement ) is entered into on January , 2013 by and between Arrowhead Research Corporation, a Delaware corporation (the Company ), and the Purchaser identified on the signature page hereto (the Purchas
Read more →ARWRPRESS RELEASE Press Release
Arrowhead Reports Fiscal 2012 Fourth Quarter and Year-End Financial Results PASADENA, Calif. December 20, 2012 Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced financial results for its fiscal 2012 fourth quarter and year ended Sep
Read more →ARWRINVESTOR SUBSCRIPTION AGREEMENT This Investor Subscription Agreement (this Agreement ) is entered into on December , 2012 by and between Arrowhead Research Corporation, a Delaware corporation (the Company ), and the Purc
INVESTOR SUBSCRIPTION AGREEMENT This Investor Subscription Agreement (this Agreement ) is entered into on December , 2012 by and between Arrowhead Research Corporation, a Delaware corporation (the Company ), and the Purchaser identified on the signature page hereto (the Purcha
Read more →ARWRSECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this Agreement ) is dated as of
SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this Agreement ) is dated as of August 10, 2012 between Arrowhead Research Corporation, a Delaware corporation (the Company ), and each purchaser identified on the signature pages hereto (each, including its suc
Read more →Competitive Position
How ARWR ranks across every disease it competes inCompetitive Position is a premium feature
See how ARWR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial